The US FDA has ordered BioNTech to immediately halt its Phase I/II trial of BNT165e, a malaria vaccine candidate, pending ...

T he parasite that causes malaria requires precise control of gene expression to progress through the various stages of its complex life cycle. A new study, by a multinational team of researchers ...

The FDA has placed a hold on BioNTech’s phase 1/2a trial, pausing the company’s efforts to develop a RNA-based vaccine for malaria prevention. The hold includes BioNTech’s investigational ...

The Ministry of Health is set to conduct a second phase of Seasonal Malaria Chemoprevention (SMC) in Turkana Central Subcounty in June.This is after the first phase was implemented in 2024 after the ...

BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with regulators on next steps.

Epigenetics are one of life's primary drivers of adaptations. They are why human beings who live at high altitude have more ...

have advanced a novel drug combination for malaria into a phase 3 programme, raising hopes of a regimen that could be used to treat resistant infections. The pairing of novel drug ganaplacide with ...

a Swiss-based not-for-profit working to bring affordable drugs to places where malaria kills an estimated 600,000 people per year. If phase one trials detect no serious side effects, broader ...